Astellas Likely To Cede U.S. Rights to Vernakalant, Cardiome CEO Says
This article was originally published in PharmAsia News
Executive Summary
Cardiome Pharma will likely be announcing a change in ownership for the U.S. rights to the I.V. version of its cardiovascular drug vernakalant by the end of the first quarter, CEO Doug Janzen told analysts on an earnings call
You may also be interested in...
Merck Consolidates All Rights To Vernakalant By Assuming North American Rights From Astellas
Merck & Co. is acquiring North American rights to intravenous vernakalant from Astellas Pharma's U.S. subsidiary, Merck announced on July 26. The agreement will consolidate its interest in the cardiovascular drug to include worldwide rights to both the IV and oral formulations
Merck Consolidates All Rights To Vernakalant By Assuming North American Rights From Astellas
Merck & Co. is acquiring North American rights to intravenous vernakalant from Astellas Pharma's U.S. subsidiary, Merck announced on July 26. The agreement will consolidate its interest in the cardiovascular drug to include worldwide rights to both the IV and oral formulations
Cardiome/Astellas' Kynapid Approval Seems Likely For Limited Indication, If Additional Trial Holds Up
Atrial fibrillation drug has been languishing after "approvable" letter - but approval now seems in the cards for limited indication.